User Profile
Corporate
Careers
FAQ
Blog
Pricing
Social
General Modals
Advanced Modals
Search
Wizards
2025 Leading Edge Research Grant Program
Lung cancer continues to be the number one cause of cancer deaths worldwide, accounting for an estimated 127,070 deaths annually in the United States alone1 . Despite being the most common cancer killer for both men and women, lung cancer research remains critically underfunded. To help close this gap and improve outcomes, the goal of the 2024 LCRF Leading Edge Research Grant Program is to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research. 2024 LCRF Leading Edge Research Grant Program will provide $150,000 over a period of two years for projects including but not limited to the following topics:
• Lung cancer biology
• Risk reduction and screening for early detection
• Identification of new biomarkers
• Development of more effective and less toxic therapies including but not limited to targeted and immune-therapies
• Genetic and gene-environment interactions
• Interactions and contributions of multiple factors (e.g. smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes
• Mechanisms of sensitivity and resistance to lung cancer therapies
• Bioengineering approaches to understanding and/or treating lung cancer (i.e., theranostics, biomaterials, nanotechnology, controlled-drug release, and gene-therapy)
• Supportive measures for people with lung cancer and their families
• Identification of metabolic vulnerabilities in lung cancer
Budget Requirements The maximum award amount is $150,000 for a period of two years (disbursed at $75,000 per year). Additional budget requirements and considerations include the following:
• Funding from this award may not be used to support institutional indirect / facilities and administrative costs.
• The LCRF grant must be the primary source of support for the project. Additional secondary funding (e.g. for core services support) is permitted.
• There is no limit on the amount of salary support that may be requested. However, appropriate justification for all budget items is required. Any salary requests in excess of 20% of the total budget must be explicitly justified.
• Any equipment costs must be limited and directly applicable to the research project (i.e. large, general equipment costs are not permitted).
• Direct patient care costs reimbursable by other sources may not be included.
• Travel and publication costs are permitted.
Specialties
Eligibility Requirements
Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. Applicants from US-based and international institutions are eligible to apply and may hold any residency/citizenship status. Applicants are prohibited from applying if they have received funding from the LCRF within the last 4 years. Senior investigators with more than ten years’ experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process. However, exceptions will be made for investigators with more than ten years’ experience in other disease areas or topicsIneligible investigators with these or other special circumstances may request review by contacting the LCRF grants office (see Inquiries section below) before submitting an application.
Sponsor Details
Sponsor Institute/Organizations: Lung Cancer Research Foundation
Sponsor Type:
Address: 501 7th Avenue, Suite 401 New York, NY 10018 United States
Legal & Affiliation Disclaimer
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Grant
Letter Of Intent Deadline:
Mar 03, 2025
Final Deadline:
Jun 02, 2025
Funding Amount:
$150,000
Host Details
Affiliation: Lung Cancer Research Foundation
Address: 501 7th Avenue, Suite 401 New York, NY 10018 United States
Website URL: https://www.lungcancerresearchfoundation.org/wp-content/uploads/2024-LCRF-Leading-Edge-Proposal-Final.pdf
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.
Invite Gmail Contacts